1 / 17

What is Biotechnology

What is Biotechnology. Biotechnology is a broad term that applies to all practical uses of living organisms -- anything from microorganisms used in the fermentation of beer to the most sophisticated application of gene therapy. BACKGROUND & OVERVIEW. Risky Market

chas
Download Presentation

What is Biotechnology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What is Biotechnology Biotechnology is a broad term that applies to all practical uses of living organisms -- anything from microorganisms used in the fermentation of beer to the most sophisticated application of gene therapy.

  2. BACKGROUND & OVERVIEW • Risky Market • Uncertainty Switch from Biotech to Pharma. • Affect of Economic Fluctuations

  3. The Mapping of Human Genome Fast Drug Approval Convergence of Nanotechnology with Biotechnology Advanced Computer Technology Databases Partnerships and Collaborations New financing in Biotechnology Increase in Biotech IPO’s BACKGROUND & OVERVIEW

  4. CLINICAL TRIALS & FDA • What is FDA (Food and Drug Administration)

  5. Pre-Clinical Trials • Studies in cell cultures and animals • 1 in 1000 make it to human testing • Patents last 20 years from this point • Last average about 5 years

  6. Phase 1 • First use of drug in humans • Test for safety and side effect • Limited number of patients • Ranges from 1 to 3 years • Chances just under 30%

  7. Phase 2 • Test for ideal dosing range of the drug • Larger number of patients • Last average of 2 years • 60% of chance to be approved

  8. Phase 3 • Treatments compared to common or standard therapies • Random choosing • Goal ; experimental therapy more beneficial than standard therapy • Double blind therapies • At least 1000 patients • Averages between 3 and 4 years • 70% chance of being approved at this point

  9. Phase 4 • To continue evaluation of the drug’s safety • This stage starts after the drug is on the market

  10. For the investor • Costs and time consuming • Ranges between $350 million and $500 million • Companies with many product on the market • Large pipeline • Cash for funding new drugs

  11. INVESTING IN BIOTECH STOCKS (DO’S ) • A Small Part of a Well-Diversified Portfolio • Products That are in Late Stage Clinical Trials • Significant Partnership Arrangements • Stocks with Broad Pipelines • Avoid Stocks That are Hyped in the Press

  12. CLPA (Nasdaq)dropped 69% in one day

  13. INVESTING IN BIOTECH STOCKS (DO’S Continued) • Be Passionate • Learn All About Your Company's Biotechnology • Know Your Risk Tolerance • Invest Money That You Don’t Need

  14. INVESTING IN BIOTECH STOCKS (DONT’S) • Don’t Forget About the Business • Don’t Buy a One-Hit Wonder • Don’t Buy on Margin

  15. HOW TO EDUCATE YOURSELF • Ernst and Young’s Biotech 99 Report • Access Excellence by National Health Museum • Tutorials at Street.com • Scientific American Articles • BioMedNet.com’s Daily Newsletter

  16. HOW TO FIND NEXT HOT BIOTECH STOCK • Red Herring Magazine • FDA Approval Process • Center Watch web page (tracks clinical trials) • BioSpace.com • FDA Web Site (upcoming meetings) • Pay Attention to Alliances • Want Free Trading Advice

More Related